Perceptive Advisors LLC Makes New Investment in Structure Therapeutics Inc. (NASDAQ:GPCR)

Perceptive Advisors LLC acquired a new stake in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 34,852 shares of the company’s stock, valued at approximately $1,369,000. Perceptive Advisors LLC owned 0.07% of Structure Therapeutics as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Sandia Investment Management LP purchased a new stake in Structure Therapeutics during the 2nd quarter worth $39,000. Quarry LP purchased a new stake in Structure Therapeutics during the 2nd quarter worth approximately $79,000. Sectoral Asset Management Inc. acquired a new position in shares of Structure Therapeutics in the 4th quarter valued at approximately $139,000. ADAR1 Capital Management LLC acquired a new position in shares of Structure Therapeutics in the 4th quarter valued at approximately $163,000. Finally, Sei Investments Co. purchased a new position in shares of Structure Therapeutics during the 2nd quarter valued at approximately $212,000. 91.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 price target on shares of Structure Therapeutics in a report on Monday, September 23rd. BMO Capital Markets increased their price target on shares of Structure Therapeutics from $83.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, June 7th. JMP Securities lowered their price objective on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a report on Friday, August 9th. Finally, Morgan Stanley initiated coverage on Structure Therapeutics in a research note on Monday, September 23rd. They set an “overweight” rating and a $118.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $88.43.

Structure Therapeutics Stock Up 0.5 %

Shares of GPCR stock opened at $41.75 on Monday. The company has a market cap of $1.95 billion, a P/E ratio of -54.22 and a beta of -3.52. The business has a 50 day moving average of $38.14 and a two-hundred day moving average of $39.85. Structure Therapeutics Inc. has a 52 week low of $26.61 and a 52 week high of $75.02.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. Analysts expect that Structure Therapeutics Inc. will post -0.86 EPS for the current fiscal year.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.